Drugmakers Valeant Pharmaceuticals International Inc. and Turing Pharmaceuticals AG boosted the prices of newly acquired drugs to meet preset profit targets, congressional investigators wrote in memos that summarized internal company documents they obtained.
Read Full Article »
